Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

drisapersen

National Institute for Health and Care Excellence NICE logo

NICE backs first Duchenne muscular dystrophy drug

Reverses original decision to reject the therapy in favour of more data

- PMLiVE

Dr Antoine Yver moves from AstraZeneca to Daiichi Sankyo

He becomes global head, oncology research and development

- PMLiVE

FDA rejects PTC’s application for muscular dystrophy drug

Says Translarna filing not “sufficiently complete” to permit full review

- PMLiVE

Daiichi Sankyo collaborates on e-patient AF resource

Will work with European platform People Who on new illness profile

Daiichi Sankyo logo

Daiichi Sankyo begins sharing clinical trial data online

Joins the likes of GSK, Lilly, UCB and Astellas in opening up its records

Daiichi Sankyo logo

Daiichi Sankyo to shut down German antibody unit U3

Will transfer its operations to a research unit in Japan

Biomarin

FDA panel rejects BioMarin’s muscular dystrophy drug

Fails to convince committee of its safety and efficacy

Daiichi Sankyo logo

Daiichi Sankyo cuts a swathe through US workforce

Plans to shed upto 1,200 jobs across the US

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

Daiichi Sankyo logo

Daiichi Sankyo licenses clot-busting antibody

New drug TS23 could be more much effective for ischemic stroke

Daiichi Sankyo logo

NICE recommends Daiichi Sankyo’s Lixiana for DVT and PE

Institute's final guidance concludes the novel oral anticoagulant is cost effective

Daiichi Sankyo logo

Daiichi’s new anticoagulant recommended by NICE

Lixiana nears NHS funding approval for certain patients with atrial fibrillation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links